Meeting
2020 Gastrointestinal Cancers Symposium
Predictors of immunotherapy (IO) response in hepatocellular carcinoma (HCC).
Authors
Samantha Ann Armstrong
Indiana University School of Medicine, Indianapolis, IN
Samantha Ann Armstrong , Bhavana Pendurthi Singh , Monika Kulasekaran , Petra Prins , Aiwu Ruth He
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 555)
Abstract #
555
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
First Author: Oxana V. Crysler
Poster
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
First Author: Benjamin Miron
Poster
2020 Gastrointestinal Cancers Symposium
Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
First Author: Mohammed Al-Jumayli